Overview

Huperzine for Cognitive and Functional Impairment in Schizophrenia

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Huperzine is a natural plant product with procognitive properties in patients with Alzheimer's disease. Cognitive difficulties hamper functioning in schizophrenia as well. The present study will investigate whether huperzine improves cognition and functioning in patients with schizophrenia.
Phase:
Phase 2
Details
Lead Sponsor:
Biomedisyn Corporation
Collaborator:
Yale University
Treatments:
Huperzine A